The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck
Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors.
 
Ken Kato
Research Funding - Lilly (Inst); Merck Serono (Inst); Ovo Pharma (Inst); Shionogi (Inst)
 
Takashi Kojima
Research Funding - Merck Serono (Inst); Ono Pharmaceutical (Inst)
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst)
 
Kei Muro
Honoraria - Chugai Pharma; Takeda; Yakult Honsha
Consulting or Advisory Role - Takeda
 
Hiroki Hara
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Keisho Chin
No Relationships to Disclose
 
Thomas Goddemeier
Employment - Merck KGaA
 
Morihiro Watanabe
No Relationships to Disclose
 
Toshihiko Doi
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; Nippon Boehringer Ingelheim; Novartis; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)